An observational study in Pulmonary Hypertension and Metal Poison, sponsored by Jiapeng Huang. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Jiapeng Huang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 53rd largest by planned enrollment of the 107 observational ones that give a count, is one of 10 that started in 2020, is one of 109 observational ones, reaches primary completion later than 59 of the 84 other live ones, and was the 306th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of California, Davis · Sites in United States
Ages up to 28 days
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States
Ages 18+
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
397 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 114 · Phase 3 75 · Phase 4 38
First in 1992; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 110 across 380 observational studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 286 interventional studies, 108 across the 107 observational. Of the 274 that completed or were terminated, 139 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 397 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jiapeng Huang as lead sponsor.
Jiapeng Huang has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
21 of the studies in Hypertension, Pulmonary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT05442671Children's Hospital of PhiladelphiaiTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH | 2026-12-31 |
| NCT04808596University of Kansas Medical CenterPulmonary Hypertension Biorepository and Registry | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigators plan to recruit 50 PAH patients from UofL PAH Clinic, with various degrees of severity (25 intermediate risk patients and 20 high risk patients) and 10 age and gender matched controls. PAH patients are evaluated at least every 6 months by the PAH Clinic and blood/urine samples will be obtained at each office visit. Blood, plasma and urine samples will be used to measure 31 metal levels including heavy metals (cadmium, arsenic, cobalt, lead etc.) and essential metals (calcium, copper, iron, zinc, potassium etc.) by the with ICP-MS via the service of ITEMFC. Interactions among the 31 metals in PAH patients, metal concentration differences between intermediate risk PAH, high risk PAH and control groups, the correlation between metal concentrations and the etiology, severity, duration, treatment, and progression of PAH/RV dysfunction over 12 months will be analyzed by CIEHS Biostatistics and Informatics Facility Core.
Exposures to heavy metals such arsenic, lead, cadmium have been linked to increased incidence of cardiovascular disease (CVD). However, current studies suffer from multiple drawbacks, most studies were cross sectional in design, focused on individual metals without consideration of the joint effects of multiple metals, and did not examine the possible effects of essential metals in CVD. Especially, the relationship between heavy metals/essential metal dyshomeostasis and right ventricular (RV) dysfunction/pulmonary hypertension (PAH), is less investigated. Investigators hypothesize that increased toxic heavy metals and/or essential metal dyshomeostasis impact hypoxia response, endothelial dysfunction, perivascular inflammation and vascular remodeling of the pulmonary vasculature, and are important pathogenic initiators/stimulators during the progression of PAH and associated RV remodeling/dysfunction.
Investigators plan to recruit 50 PAH patients from UofL PAH Clinic, with various degrees of severity (25 intermediate risk patients and 20 high risk patients) and 10 age and gender matched controls. PAH patients are evaluated at least every 6 months by the PAH Clinic and blood/urine samples will be obtained at each office visit. Blood, plasma and urine samples will be used to measure 31 metal levels including heavy metals (cadmium, arsenic, cobalt, lead etc.) and essential metals (calcium, copper, iron, zinc, potassium etc.) by the with ICP-MS via the service of ITEMFC. Interactions among the 31 metals in PAH patients, metal concentration differences between intermediate risk PAH, high risk PAH and control groups, the correlation between metal concentrations and the etiology, severity, duration, treatment, and progression of PAH/RV dysfunction over 12 months will be analyzed by CIEHS Biostatistics and Informatics Facility Core.
Heavy metals have the potential of generating reactive oxygen species (ROS) and oxidative stress whenever the release of ROS exceeds endogenous antioxidant capacity. Therefore, investigators hypothesize that heavy metal/essential metal dyshomeostasis could induce oxidative stress responses, activate two key pulmonary vasculature regulators (endothelin 1 and hypoxia inducible factor (HIF) pathways), and in turn contributes to the PAH pathogenesis and RV dysfunction. Oxidative stress, endothelin 1 and HIF pathway markers in the blood will be measured with ELISA kits in both PAH and control groups. Investigators will perform comprehensive correlation analysis between metal levels, oxidative stress markers, endothelin 1 and HIF pathway markers, and quantitative clinical biomarkers such as hemodynamic, laboratory and functional data in PAH patients. Furthermore, investigators will perform correlation analysis between blood levels of oxidative stress, endothelin 1 and HIF pathway markers and the patients' dietary intake of antioxidant vegetables.
Patients with pulmonary hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
age and gender matched controls
Diagnostic Test: Metal level measurements
Pulmonary Hypertension Patients with Various Degree of Severity
Diagnostic Test: Metal level measurements
Measure multiple metal levels
Metal levels in control and pulmonary hypertension groups
Metal levels in control and pulmonary hypertension groups
Time frame: up to 12 months
Right heart catheterization data
mean pulmonary artery pressure (mmHg)
Time frame: up to 12 months
Pulmonary hypertension risk scores (Registry to Evaluate Early and Long-Term PAH Disease Management)
Pulmonary hypertension risk scores, 0-10, the higher score means a worse outcome.
Time frame: up to 12 months
Mortality
death
Time frame: up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2020 (actual). Primary completion is estimated for Dec 2028, 96 months after the start.
Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 96 months is above that.
Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.